Orforglipron

What it is claimed to help

These are the uses attached to Orforglipron in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.

What the human evidence actually is

Approved on the ATTAIN phase 3 programme, which enrolled over 4,500 people with obesity. Participants on the highest dose lost an average of about 27 lb in ATTAIN-1. It is a once-daily tablet with no food, water or timing restrictions — unlike oral semaglutide. Lilly is also studying it in type 2 diabetes, sleep apnea, knee osteoarthritis, hypertension, peripheral artery disease and stress urinary incontinence.

How it is supposed to work

Binds and activates the GLP-1 receptor in appetite-regulating brain regions. Because it is a small molecule rather than a peptide, it survives the gut and does not need injection — the problem that has limited peptide drugs since insulin.

Safety

Boxed warning for thyroid C-cell tumours, though notably orforglipron is not pharmacologically active in rats or mice and did not produce tumours in rodents. Pancreatitis, severe GI reactions, acute kidney injury from volume depletion, hypoglycaemia, gallbladder disease and diabetic retinopathy complications. Nausea, constipation, diarrhoea and hair loss are common.

Storage and handling

Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.